Theriva Biologics, Inc.
TOVXAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | upgrade | Hold →Buy | Mar 31, 2026 |
| Maxim Group | downgrade | Buy →Hold | May 8, 2025 |
| Maxim Group | maintain | Buy | Nov 13, 2024 |
Earnings History
Next report: Nov 17, 2026 · EPS est. $-0.06| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.07 | $-0.06 | — | — |
| May 5, 2026 | $-0.05 | $-0.05 | $300.0K | $300.0K |
| Mar 12, 2026 | $1.85 | $-0.43 | — | — |
| Nov 12, 2025 | $-0.45 | $-0.38 | — | — |
| Aug 11, 2025 | $-1.93 | $-0.38 | — | — |
| May 14, 2025 | $-1.55 | $-4.19 | — | — |
| Mar 24, 2025 | $6.03 | $-7.22 | — | — |
| Nov 12, 2024 | $-6.81 | $-6.25 | — | — |
News
– Theriva received a $350,000 upfront payment at closing and is eligible for up to $91 million in regulatory and sales milestones, along with low single-digit royalties on net product sales – – Biossil to assume all responsibility and costs for future development and commercialization of the antibiotic-degrading enzyme portfolio – ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed…
- Publication in this premier journal after rigorous peer review validates the VIRAGE study and supports the continued evaluation of VCN-01 in the treatment of metastatic pancreatic cancer - - Data are consistent with an immune mediated mechanism of action for VCN-01 that may enhance the antitumor effects of a range of coadministered pancreatic cancer therapies - - The feasibility of administering more frequent repeated VCN-01 doses to potentially improve clinical outcomes in metastatic pancreat…
- Se ha administrado la primera dosis a los pacientes en el estudio clínico VIRAGE2 de Fase IIa, que evalúa la administración con mayor frecuencia de VCN-01 (zabilugene almadenorepvec), cuyo objetivo es mejorar los resultados del tratamiento en pacientes con adenocarcinoma ductal pancreático (PDAC) metastásico - - Efectivo y equivalentes de efectivo por valor de 11,3 millones de dólares estadounidenses a 30 de junio de 2026, con liquidez suficiente hasta el primer trimestre de 2027 - ROCKVILLE, …
– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients – – Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 – ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing ther…